Nick Bassil comments on Indivior losing US Patent dispute in Lawyer Monthly


Losing a patent dispute cost this drugs firm £1 billion

Drugs manufacturer Indivior has had £1bn ($1.3 billion) wiped off their value as a result of it losing as US patent dispute over its heroin treatment substitute.

Reports indicate that the patent dispute between Reckitt Benckiser and Dr Reddy's that was first ruled upon in 2014 has taken a vicious turn, as an appeal against the 2014 decision that a patent for 'suboxone film' was not infringed upon has been rejected.

Our partner, Nick Bassil, had this to say for Lawyer Monthly: 'The impact of the decision against pharma giant Indivior, which recently pushed its shares into a tailspin, derives from the complex question of patent infringement, not validity. It's important to remember this is only a first instance judgment and the validity of the patents was upheld.'

Read the full article in Lawyer Monthly.